Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences

25-09-2024 | Ulcerative Colitis | Original Article

Low-Grade Activation of the Extrinsic Coagulation Pathway in Patients with Ulcerative Colitis

Authors: Ioannis Drygiannakis, Vassilis Valatas, Eirini Filidou, Niki Tzenaki, Evangelia Archontoulaki, Nikolas Dovrolis, Leonidas Kandilogiannakis, Georgios Kefalogiannis, Prodromos Sidiropoulos, George Kolios, Ioannis E. Koutroubakis

Published in: Digestive Diseases and Sciences

Login to get access

Abstract

Background

Ulcerative colitis (UC) increases the risk for venous thromboembolism. Tissue factor (TF) initiates the extrinsic coagulation pathway (ECP).

Aims

To investigate the correlation of UC severity with latent ECP activation and TF expression in primary colonic stromal cells (PCSC).

Methods

In plasma of 38 UC patients (31 males, disease duration 151 ± 25 months) and 28 healthy controls, exosomes and microparticles (EM) were counted. Moreover, TF protein concentration, activities of EM-bound TF (EM-TFa) and coagulation factor VII (FVIIa) were assessed. In PCSC in culture, TF mRNA (F3) from 12 patients with active UC and 7 controls was evaluated.

Results

UC patients had 4– and 3.7– times more exosomes and microparticles, respectively, than controls. TF protein in UC was correlated with several disease severity indices, such as partial Mayo score (pMs; r 0.443), albumin (− 0.362), ESR (0.353), PLT (0.575), and endoscopic Ms (eMs 0.468). EM-TFa was also significantly higher in UC and was correlated to SIBDQ (− 0.64), albumin (− 0.624), disease extent and eMs (0.422). Refractory-to-treatment patients had significantly higher TF protein, EM-TFa and FVIIa. Even within responders, the need for steroids or biologics correlated with a 2.2–times higher EM-TFa. PCSC from active UC maintained higher F3 than controls, which was correlated to pMs (0.56), albumin (− 0.543) and eMs. Treatment with cytokines further upregulated F3. P for all comparisons was < 0.05.

Conclusion

Low-grade activation of the ECP associates with clinical, endoscopic UC activity and response to treatment. TF in PCSC mirrors its systemic activity and points to them as a source.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
Koutroubakis IE. Venous thromboembolism in hospitalized inflammatory bowel disease patients: the magnitude of the problem is staggering. Am J Gastroenterol. 2008;103:2281–2283.PubMedCrossRef
2.
Gordon H, Burisch J, Ellul P et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2024;18:1–37.PubMedCrossRef
3.
4.
Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97–101.PubMedCrossRef
5.
Novacek G, Weltermann A, Sobala A et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139:779–787.PubMedCrossRef
6.
Koutroubakis IE, Sfiridaki A, Tsiolakidou G et al. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis. 2007;13:410–415.PubMedCrossRef
7.
Koutroubakis IE, Sfiridaki A, Mouzas IA et al. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:190–194.PubMedCrossRef
8.
9.
Koutroubakis IE. Unraveling the mechanisms of thrombosis in inflammatory bowel disease. Am J Gastroenterol. 2001;96:1325–1327.PubMedCrossRef
10.
Sandborn WJ, Panes J, Sands BE et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019;50:1068–1076.PubMedPubMedCentralCrossRef
11.
Kearon C, Ageno W, Cannegieter SC et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14:1480–1483.PubMedCrossRef
12.
Gao Y, Lv L, Liu S, Ma G, Su Y. Elevated levels of thrombin-generating microparticles in stored red blood cells. Vox Sang. 2013;105:11–17.PubMedCrossRef
13.
14.
15.
16.
Kambas K, Chrysanthopoulou A, Kourtzelis I et al. Endothelin-1 signaling promotes fibrosis in vitro in a bronchopulmonary dysplasia model by activating the extrinsic coagulation cascade. J Immunol. 2011;186:6568–6575.PubMedCrossRef
17.
18.
Hassan N, Efing J, Kiesel L, Bendas G, Gotte M. The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans. Cancers (Basel). 2023;15:1524.PubMedPubMedCentralCrossRef
19.
Henriksson CE, Klingenberg O, Hellum M et al. Calcium ionophore-induced de-encryption of tissue factor in monocytes is associated with extensive cell death. Thromb Res. 2007;119:621–630.PubMedCrossRef
20.
Davila M, Robles-Carrillo L, Unruh D et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation? J Thromb Haemost. 2014;12:186–196.PubMedCrossRef
21.
Engelmann B. Initiation of coagulation by tissue factor carriers in blood. Blood Cells Mol Dis. 2006;36:188–190.PubMedCrossRef
22.
Stojanovic A, Veselinovic M, Zong Y, Jakovljevic V, Pruner I, Antovic A. Increased Expression of Extracellular Vesicles Is Associated With the Procoagulant State in Patients With Established Rheumatoid Arthritis. Front Immunol. 2021;12:718845.PubMedPubMedCentralCrossRef
23.
Drygiannakis I, Valatas V, Sfakianaki O et al. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. J Crohns Colitis. 2013;7:286–300.PubMedCrossRef
24.
Filidou E, Valatas V, Drygiannakis I et al. Cytokine Receptor Profiling in Human Colonic Subepithelial Myofibroblasts: A Differential Effect of Th Polarization-Associated Cytokines in Intestinal Fibrosis. Inflamm Bowel Dis. 2018;24:2224–2241.PubMedCrossRef
25.
Bamias G, Goukos D, Laoudi E et al. Comparative study of candidate housekeeping genes for quantification of target gene messenger RNA expression by real-time PCR in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2840–2847.PubMedCrossRef
26.
Khan MM, Hattori T, Niewiarowski S, Edmunds LH, Colman RW. Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII. Thromb Haemost. 2006;95:462–468.PubMedCrossRef
27.
Faulkner LG, Alqarni S, Maraveyas A, Madden LA. Isolated tumour microparticles induce endothelial microparticle release in vitro. Blood Coagul Fibrinolysis. 2020;31:35–42.PubMedCrossRef
28.
Palkovits J, Novacek G, Kollars M et al. Tissue factor exposing microparticles in inflammatory bowel disease. J Crohns Colitis. 2013;7:222–229.PubMedCrossRef
29.
Fonseca R, Cesarman-Maus G, Braggio E. Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer. J Clin Oncol. 2017;35:2217–2218.PubMedCrossRef
30.
Claussen C, Rausch AV, Lezius S et al. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer. Thromb Res. 2016;141:39–48.PubMedCrossRef
31.
Thaler J, Koder S, Kornek G, Pabinger I, Ay C. Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res. 2014;163:145–150.PubMedCrossRef
32.
Hisada Y, Thalin C, Lundstrom S, Wallen H, Mackman N. Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients. Thromb Res. 2018;165:1–5.PubMedPubMedCentralCrossRef
33.
Stark K, Schubert I, Joshi U et al. Distinct Pathogenesis of Pancreatic Cancer Microvesicle-Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo. Arterioscler Thromb Vasc Biol. 2018;38:772–786.PubMedCrossRef
34.
Cohen JG, Prendergast E, Geddings JE et al. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecol Oncol. 2017;146:146–152.PubMedCrossRef
35.
Fricke A, Ullrich PV, Cimniak AFV et al. Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism. BMC Cancer. 2017;17:527.PubMedPubMedCentralCrossRef
36.
Mi XK, Liu QR, Zhu L, Sang MX, Guo LR, Shan BE. Mechanism of the high coagulation state of breast cancer tissue factor. Eur Rev Med Pharmacol Sci. 2017;21:2167–2171.PubMed
37.
Gheldof D, Chatelain C, Dogne JM, Mullier F. Microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res. 2014;134:213–214.PubMedCrossRef
38.
Thaler J, Pabinger I, Sperr WR, Ay C. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res. 2014;133:303–305.PubMedCrossRef
39.
Angelini A, Miscia S, Centurione MA, Di Pietro R, Centurione L. Predictive value of microparticle-associated tissue factor activity for permeability glycoprotein-mediated multidrug resistance in cancer. Oncol Lett. 2016;12:3273–3277.PubMedPubMedCentralCrossRef
40.
41.
Mendoza CE, Brant EJ, McDermott ML et al. Elevated Microparticle Tissue Factor Activity Differentiates Patients With Venous Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis. Kidney Int Rep. 2019;4:1617–1629.PubMedPubMedCentralCrossRef
42.
Chaturvedi S, Cockrell E, Espinola R et al. Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. Thromb Res. 2015;135:102–108.PubMedCrossRef
43.
Willemze R, Bradford RL, Mooberry MJ, Roubey RA, Key NS. Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. Thromb Res. 2014;133:187–189.PubMedCrossRef
44.
Rautou PE, Vion AC, Luyendyk JP, Mackman N. Circulating microparticle tissue factor activity is increased in patients with cirrhosis. Hepatology. 2014;60:1793–1795.PubMedCrossRef
45.
Zhang X, McGeoch SC, Johnstone AM et al. Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J Thromb Thrombolysis. 2014;37:455–463.PubMedCrossRef
46.
Woei AJFJ, Tesselaar ME, Garcia Rodriguez P, Romijn FP, Bertina RM, Osanto S. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Br J Cancer. 2016;115:332–338.CrossRef
47.
Kandilogiannakis L, Filidou E, Drygiannakis I et al. Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis. Stem Cells Int. 2021;2021:9929461.PubMedPubMedCentralCrossRef
48.
Szotowski B, Antoniak S, Goldin-Lang P et al. Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. Cardiovasc Res. 2007;73:806–812.PubMedCrossRef
49.
Papageorgiou L, Alhaj Hussen K, Thouroude S et al. Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process. TH Open. 2019;3:e340–e347.PubMedPubMedCentralCrossRef
50.
Wright A, Snyder OL, He H, Christenson LK, Fleming S, Weiss ML. Procoagulant Activity of Umbilical Cord-Derived Mesenchymal Stromal Cells’ Extracellular Vesicles (MSC-EVs). Int J Mol Sci. 2023;24:9216.PubMedPubMedCentralCrossRef
51.
Manousos ON, Giannadaki E, Mouzas IA et al. Ulcerative colitis is as common in Crete as in northern Europe: a 5-year prospective study. Eur J Gastroenterol Hepatol. 1996;8:893–898.PubMed
Metadata
Title
Low-Grade Activation of the Extrinsic Coagulation Pathway in Patients with Ulcerative Colitis
Authors
Ioannis Drygiannakis
Vassilis Valatas
Eirini Filidou
Niki Tzenaki
Evangelia Archontoulaki
Nikolas Dovrolis
Leonidas Kandilogiannakis
Georgios Kefalogiannis
Prodromos Sidiropoulos
George Kolios
Ioannis E. Koutroubakis
Publication date
25-09-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08640-1

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits